N

Nykode Therapeutics ASA
OSE:NYKD

Watchlist Manager
Nykode Therapeutics ASA
OSE:NYKD
Watchlist
Price: 2.466 NOK -2.14% Market Closed
Market Cap: 805.3m NOK

Intrinsic Value

The intrinsic value of one NYKD stock under the Base Case scenario is 0.49 NOK. Compared to the current market price of 2.466 NOK, Nykode Therapeutics ASA is Overvalued by 80%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

NYKD Intrinsic Value
0.49 NOK
Overvaluation 80%
Intrinsic Value
Price
N
Worst Case
Base Case
Best Case

Valuation History
Nykode Therapeutics ASA

What is Valuation History?
Ask AI Assistant
What other research platforms think about NYKD?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is NYKD valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Nykode Therapeutics ASA.

Explain Valuation
Compare NYKD to

Fundamental Analysis

Company Overview
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about NYKD?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Nykode Therapeutics ASA

Current Assets 67m
Receivables 3m
Other Current Assets 64m
Non-Current Assets 39m
PP&E 6.2m
Intangibles 70k
Other Non-Current Assets 32.7m
Current Liabilities 3.9m
Other Current Liabilities 3.9m
Non-Current Liabilities 2.5m
Long-Term Debt 1.6m
Other Non-Current Liabilities 920k
Efficiency

Free Cash Flow Analysis
Nykode Therapeutics ASA

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Nykode Therapeutics ASA

Revenue
6.8m USD
Operating Expenses
-33.3m USD
Operating Income
-26.5m USD
Other Expenses
15.5m USD
Net Income
-11m USD
Fundamental Scores

NYKD Profitability Score
Profitability Due Diligence

Nykode Therapeutics ASA's profitability score is 21/100. The higher the profitability score, the more profitable the company is.

21/100
Profitability
Score

Nykode Therapeutics ASA's profitability score is 21/100. The higher the profitability score, the more profitable the company is.

NYKD Solvency Score
Solvency Due Diligence

Nykode Therapeutics ASA's solvency score is 68/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
68/100
Solvency
Score

Nykode Therapeutics ASA's solvency score is 68/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

NYKD Price Targets Summary
Nykode Therapeutics ASA

Wall Street analysts forecast NYKD stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NYKD is 5.457 NOK with a low forecast of 2.222 NOK and a high forecast of 8.925 NOK.

Lowest
Price Target
2.222 NOK
10% Downside
Average
Price Target
5.457 NOK
121% Upside
Highest
Price Target
8.925 NOK
262% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for NYKD is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y
What is the Intrinsic Value of one NYKD stock?

The intrinsic value of one NYKD stock under the Base Case scenario is 0.49 NOK.

Is NYKD stock undervalued or overvalued?

Compared to the current market price of 2.466 NOK, Nykode Therapeutics ASA is Overvalued by 80%.

Back to Top